These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8984030)

  • 1. Intracolonic administration of zileuton, a selective 5-lipoxygenase inhibitor, accelerates healing in a rat model of chronic colitis.
    Bertrán X; Mañé J; Fernández-Bañares F; Castellá E; Bartolí R; Ojanguren I; Esteve M; Gassull MA
    Gut; 1996 Jun; 38(6):899-904. PubMed ID: 8984030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats.
    Zingarelli B; Squadrito F; Graziani P; Camerini R; Caputi AP
    Agents Actions; 1993 Jul; 39(3-4):150-6. PubMed ID: 7905704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-ASA-glutamate protects rats from inflammatory bowel disease induced by intracolonic administration of trinitrobenzensulfonic acid.
    Clerici C; Gentili G; Pellicciari R; Gresele P; Mezzasoma AM; Giansanti M; Clementi M; Bartoli G; Balò S; Modesto R; Aburbeh AG; Morelli O; Morelli A
    Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):385-90. PubMed ID: 9789134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
    Hawkey CJ; Dube LM; Rountree LV; Linnen PJ; Lancaster JF
    Gastroenterology; 1997 Mar; 112(3):718-24. PubMed ID: 9041232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis.
    Vilaseca J; Salas A; Guarner F; Rodriguez R; Malagelada JR
    Gastroenterology; 1990 Feb; 98(2):269-77. PubMed ID: 2153086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cyclooxygenase and lipoxygenase inhibition on eicosanoids and healing of acetic acid colitis in rats.
    LeDuc LE; Su KC; Guth E; Reedy T; Guth PH
    Dig Dis Sci; 1993 Feb; 38(2):289-94. PubMed ID: 8425441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease.
    Wallace JL; MacNaughton WK; Morris GP; Beck PL
    Gastroenterology; 1989 Jan; 96(1):29-36. PubMed ID: 2535830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
    Pallio G; Bitto A; Pizzino G; Galfo F; Irrera N; Minutoli L; Arcoraci V; Squadrito G; Macrì A; Squadrito F; Altavilla D
    Eur J Pharmacol; 2016 Oct; 789():152-162. PubMed ID: 27450484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
    Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
    Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of epidermal growth factor on experimental colitis in the rat.
    Luck MS; Bass P
    J Pharmacol Exp Ther; 1993 Feb; 264(2):984-90. PubMed ID: 8382288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
    Casellas F; Papo M; Guarner F; Antolín M; Segura RM; Armengol JR; Malagelada JR
    Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):221-6. PubMed ID: 7743303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a selective 5-lipoxygenase inhibitor, zileuton, on tissue damage in acute colonic inflammation in rats.
    Zarif A; Eiznhamer D; Callaghan C; Doria MI; Broutman L; Keshavarzian A
    Inflammation; 1996 Jun; 20(3):217-27. PubMed ID: 8796377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
    Weinblatt ME; Kremer JM; Coblyn JS; Helfgott S; Maier AL; Petrillo G; Henson B; Rubin P; Sperling R
    J Rheumatol; 1992 Oct; 19(10):1537-41. PubMed ID: 1334515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM; Spruce KE; Crawley GC; Walker ER; Foster SJ
    Br J Pharmacol; 1992 Dec; 107(4):1042-7. PubMed ID: 1334748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
    Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
    Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis.
    Wallace JL; Keenan CM; Gale D; Shoupe TS
    Gastroenterology; 1992 Jan; 102(1):18-27. PubMed ID: 1309357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
    Israel E; Cohn J; Dubé L; Drazen JM
    JAMA; 1996 Mar; 275(12):931-6. PubMed ID: 8598621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon.
    Videla S; Vilaseca J; Guarner F; Salas A; Treserra F; Crespo E; Antolín M; Malagelada JR
    Gut; 1994 Aug; 35(8):1090-7. PubMed ID: 7926912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease.
    Rask-Madsen J; Bukhave K; Laursen LS; Lauritsen K
    Agents Actions; 1992; Spec No():C37-46. PubMed ID: 1359745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.
    Awni WM; Braeckman RA; Cavanaugh JH; Locke CS; Linnen PJ; Granneman GR; Dubé LM
    Clin Pharmacokinet; 1995; 29 Suppl 2():112-24. PubMed ID: 8620667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.